ImmunityBio Inc Ordinary Shares IBRX 深 滬
已收盤 08-08 16:00:00 美东时间
2.44
+0.035
+1.46%
華盛通- 最 高2.44
- 今 開2.415
- 成交量 476.17万股
- 最 低 2.38
- 昨 收 2.405
- 總市值 21.55亿
- 52周最高 7.48
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 1.83
- 委 比 -32.89%
- 總股本 8.83亿
- 歷史最高 45.42
- 量 比 0.75
- 振 幅 2.49%
- 歷史最低 0.93
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
ImmunityBio ( ($IBRX) ) has shared an update. On July 29, 2025, the United Stat...
今天 04:57
ImmunityBio Reports Revenue Growth Amidst Continued Investments
Immunitybio Inc ( ($IBRX) ) has released its Q2 earnings. Here is a breakdown o...
08-06 13:12
ImmunityBio Q2 EPS $(0.10) Beats $(0.11) Estimate, Sales $26.425M Beat $21.488M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 50 percent increase over losses of $(0.20) per share from the same
08-05 19:41
ImmunityBio secures $80M financing
ImmunityBio (NASDAQ:IBRX) has secured new financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement with two in...
07-25 18:10
ImmunityBio reports Q2 revenue above consensus
ImmunityBio press release (NASDAQ:IBRX): Q2 revenue of $26.4M (+60.0% Q/Q) beats by $4.45M. More on ImmunityBio ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval ImmunityBio: Hi...
07-25 18:07
孙正义：《洛杉矶时报》将上市
《洛杉矶时报》老板帕特里克・孙正义（Patrick Soon-Shiong）周一在接受电视采访时表示，这家有着 143 年历史的报纸计划在未来一年内上市，旨...
07-22 16:29
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.
07-22 14:36
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the di...
07-09 20:30
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.
07-08 19:19
Reported Earlier, ImmunityBio Gains UK Marketing Authorization for ANKTIVA With Bacillus Calmette-Guérin In Bladder Cancer, Expanding Breakthrough Therapy Beyond U.S
ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, helping eliminate cancerAlready approved in the U.S. and designated as
07-08 14:29
